Nonagen Therapeutics is developing humanized monoclonal antibodies that target and neutralize novel angiogenic and immune molecules to treat human diseases, particularly cancer. This approach addresses the need for effective therapeutics that can improve treatment outcomes for cancer patients.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers rely on angiogenesis (the formation of new blood vessels) and immune evasion to grow and spread. Current cancer treatments may not effectively target these mechanisms, leading to limited efficacy and potential for recurrence.
Solution
Nonagen Therapeutics is creating humanized monoclonal antibodies designed to selectively bind to and neutralize specific angiogenic and immune-modulating molecules that are critical for tumor survival and progression. By targeting these key pathways, the antibodies aim to disrupt the tumor microenvironment, inhibit angiogenesis, and enhance the body's immune response against cancer cells. This approach seeks to improve treatment outcomes and provide more effective therapies for patients with various types of cancer.
Target Audience
The primary target audience includes pharmaceutical companies, oncologists, and cancer researchers seeking innovative therapeutic approaches for cancer treatment.
Features
- Humanized monoclonal antibodies with high affinity and specificity for novel angiogenic targets
- Antibodies engineered to modulate the tumor microenvironment and promote immune cell infiltration
- Preclinical validation demonstrating anti-tumor activity in relevant cancer models
- Development pipeline focused on multiple cancer indications with unmet medical needs